Moderna's mFLUSIVA, a seasonal flu vaccine, has received FDA approval for adults aged 50 and older. This marks a significant expansion of Moderna's product portfolio beyond COVID-19 and positions it to compete in the established flu vaccine market.
Moderna has secured FDA approval for its seasonal flu vaccine, mFLUSIVA, for adults 50 years and older. This is a crucial development as it diversifies Moderna's revenue streams beyond its COVID-19 vaccine, Spikevax, and allows it to enter the large and recurring seasonal flu vaccine market. The approval is based on successful Phase 3 trials, with a standard approval for ages 50-64 and accelerated approval for 65+. While the immediate stock reaction was slightly negative, likely due to broader market sentiment or profit-taking, this approval provides a long-term growth opportunity for Moderna, with the vaccine expected to be available for the 2026-2027 season. The company also has international regulatory reviews underway, indicating further market expansion potential.